Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01531088 · ClinicalTrials.gov registry record · NA
Enhancing the Detection and Management of Adverse Drug Events in Nursing Homes
A NA study of Adverse Drug Events, sponsored by University of Pittsburgh.
- Completed
- Registry status
- NA
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT01531088: Completed NA study of Adverse Drug Events, sponsored by University of Pittsburgh.
NCT01531088 is a NA study of Adverse Drug Events that has completed, run by University of Pittsburgh. The registered enrollment target is 36 participants, below the 783-participant average among 6 other Adverse Drug Events trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01531088, a NA study of Adverse Drug Events, has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- NA
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
Adverse drug events (ADEs) are the most clinically significant and costly medication-related problems in nursing homes (NH) and are associated with an estimated 93,000 deaths a year and as much as $4 billion of excess healthcare expenditures. Current ADE detection and management strategies that rely on pharmacist retrospective chart reviews (i.e., usual care) are inadequate. Active medication monitoring systems are recommended by many safety organizations as an alternative to detect and manage ADEs. These systems have been shown to be less expensive, faster, and identify ADEs not normally detected by clinicians in the hospital setting. The investigators developed and pilot-tested an active medication monitoring system for use in a single NH, where it was shown to detect ADEs with a high degree of accuracy and at a rate of nearly 2.5 times that of usual care. The long-term objective of our proposed research is to improve patient safety with respect to medications in NHs. The short-term objectives or specific aims of our proposed research are to determine if NH patients managed by physicians who receive active medication monitoring alerts have more ADEs detected, have a faster ADE management response time, and can result in more cost-savings from a societal perspective compared to usual care.
Primary Outcome
Number of adverse events detected
Conditions Studied
Interventions
- BEHAVIORAL Active medication monitoring
Study Locations (1)
Pennsylvania
- University of Pittsburgh - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2012-01 |
| Est. Completion | 2015-04 |
| Phase | NA |
What the finished NCT01531088 record still lists
NCT01531088 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 783-participant average among 6 other Adverse Drug Events trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Adverse Drug Events appearing as the primary indexed condition, and to 1 intervention - of which Active medication monitoring is the first listed.
NCT01531088 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01531088 about?
NCT01531088 is a clinical study titled "Enhancing the Detection and Management of Adverse Drug Events in Nursing Homes". Adverse drug events (ADEs) are the most clinically significant and costly medication-related problems in nursing homes (NH) and are associated with an estimated 93,000 deaths a year and as much as $4 billion of excess healthcare expenditures. Current ADE detection and management strategies that rely...
What is the current status of trial NCT01531088?
This trial is currently completed. It is a NA study. The enrollment target is 36 participants. The study started on 2012-01. Estimated completion is 2015-04.
What conditions does trial NCT01531088 study?
This clinical trial studies the following conditions: Adverse Drug Events.
What interventions are being tested in trial NCT01531088?
The interventions under investigation include: Active medication monitoring (BEHAVIORAL).
Who is sponsoring clinical trial NCT01531088?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01531088 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adverse Drug Events
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Geriatric Emergency Department Pharmacologic Harm Prevention Project
RECRUITING · NA
-
Multi-Center Medication Reconciliation Quality Improvement Study
COMPLETED · NA
-
Patient Profiling and Provider Feedback to Reduce Adverse Drug Events
COMPLETED · NA
-
The Secure Messaging for Medication Reconciliation Tool (SMMRT) Trial
COMPLETED · NA
-
Improving Safety by Basic Computerizing Outpatient Prescribing
COMPLETED · Phase 2
-
Response to Medication Registry
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia